Open-label, Randomised, 4 Parallel-group, Phase I Clinical Trial to Investigate BI 456906 Occupancy of Glucagon Receptors in Liver and Glucagon-like Peptide 1 Receptors in Pancreas in Comparison With Semaglutide After Administration of Radiolabeled Tracer in Male and Female Subjects With Obesity Using PET and MRI
Latest Information Update: 14 Nov 2024
At a glance
- Drugs Survodutide (Primary) ; Semaglutide
- Indications Obesity
- Focus Pharmacodynamics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 01 Oct 2024 Planned End Date changed from 1 Jul 2026 to 23 Mar 2026.
- 01 Oct 2024 Planned primary completion date changed from 1 Jul 2026 to 23 Mar 2026.
- 26 Aug 2024 Planned End Date changed from 1 Jun 2026 to 1 Jul 2026.